InfuSystem Holdings, Inc — fact timeline

Beverly Huss was elected as Chairman of the Board of Directors at InfuSystem Holdings, Inc.

“the newly constituted Board of Directors elected Beverly Huss to serve as the Chairman of the Board of Directors.”

InfuSystem Holdings, Inc shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm at the 2026-05-11 meeting.

“Proposal No. 4: The Company's stockholders ratified the appointment of Grant Thornton LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2026 as follows: For Against Abstain Broker Non-Votes 16,604,725 613 193,626 0”

InfuSystem Holdings, Inc shareholders approved Amendment to the 2021 Equity Plan to increase authorized shares at the 2026-05-11 meeting.

“Proposal No. 3: The Company's stockholders approved the amendment to the Company's 2021 Equity Plan to increase the number of authorized shares under the 2021 Equity Plan as follows: For Against Abstain Broker Non-Votes 10,770,778 2,199,707 100,194 3,728,285”

InfuSystem Holdings, Inc shareholders approved Advisory vote on executive compensation at the 2026-05-11 meeting.

“Proposal No. 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows: For Against Abstain Broker Non-Votes 11,915,842 1,071,346 83,491 3,728,285”

InfuSystem Holdings, Inc shareholders approved Election of Directors at the 2026-05-11 meeting.

“Proposal No. 1: The Company's Board Nominees For Against Abstain Broker Non-Votes Kenneth D. Eichenbaum, MD, MSE 11,921,195 827,929 321,555 3,728,285 Paul A. Gendron 12,614,275 276,474 179,930 3,728,285 Ronald Hundzinksi 12,368,646 611,294 90,739 3,728,285 Beverly A. Huss 11,890,777 847,243 332,659 3,728,285 Carrie Lachance 12,920,694 65,053 84,932 3,728,285 Scott Shuda 11,914,592 834,532 321,555 3,728,285 Dr. John J. Sviokla 12,227,773 521,341 321,565 3,728,285 All seven of the Company's Board nominees (Drs Eichenbaum and Sviokla, Messrs. Gendron, Hundzkinski, and Shuda and Mses. Huss and Lachance) were elected to the Board.”

InfuSystem Holdings, Inc reported first quarter ended March 31, 2026 results: revenue $33.7 million, net income $1.0 million, or $0.05 per diluted share, EPS $0.05 per diluted share. Guidance reaffirmed.

“InfuSystem Announces Financial Results for First Quarter 2026 Net Revenues of $33.7 million Representing a 3% Reduction from the Prior Year Net income of $1.0 million Adjusted EBITDA (non-GAAP) of $6.4 million Adjusted EBITDA (non-GAAP) margin expanded by 1% to 19% Reaffirms Full-Year 2026 Guidance”

InfuSystem Holdings, Inc engaged Grant Thornton LLP as its auditor.

“(the "Company") conducted a competitive selection process to determine the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The Committee invited several firms to participate in this process, including Deloitte & Touche LLP ("Deloitte"), the Company's independent registered public accounting firm for the year ended December 31, 2025. As a result of this process, following the review and evaluation of proposals from participating firms, on March 13, 2026 , the Committee approved the dismissal of Deloitte as the Company's independent registered public accounting firm and the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements as of and for the fiscal year ending December 31, 2026, and to review the Company's quarterly”

InfuSystem Holdings, Inc dismissed Deloitte & Touche LLP as its auditor.

“the Committee approved the dismissal of Deloitte as the Company's independent registered public accounting firm and the appointment of Grant Thornton LLP”

InfuSystem Holdings, Inc amended credit facility with JPMorgan Chase Bank, N.A., as administrative agent maturing July 15, 2030.

“(the “Company”) together with its direct and indirect subsidiaries (collectively, the “Borrowers”), entered into a Second Amendment to Credit Agreement (the “Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), and the lenders party thereto, which amended the Credit Agreement, dated as of February 5, 2021 (as amended by the First and Second Amendments, the “Credit Agreement”) among the Borrowers, the other loan parties party thereto, the lenders party thereto, and the Administrative Agent, providing for, among other things, an extension of the maturity date for the Credit Agreement to July 15, 2030.”

InfuSystem Holdings, Inc: Amended and Restated Certificate of Incorporation to remove obsolete blank check company provisions, designate exclusive forums, and limit officer liability under Delaware law (effective 2025-05-20).

“On May 20, 2025, the Company filed with the Secretary of State of the State of Delaware a Second Amended and Restated Certificate of Incorporation to implement the Charter Amendments, which became effective upon filing.”

Carrie Lachance changed role as President and Chief Executive Officer at InfuSystem Holdings, Inc.

“The Second Amended Agreement reflects changes in Ms. Lachance’s compensation and other terms of employment in connection with her previously announced transition from President and Chief Operating Officer of the Company to President and Chief Executive Officer of the Company that occurred on May 19, 2025.”

Ronald Hundzinski was elected as Chairman at InfuSystem Holdings, Inc.

“Following the Annual Meeting, the newly constituted Board of Directors elected Ronald Hundzinski to serve as the Chairman of the Board of Directors and disbanded the role of Executive Chairman.”

Scott Shuda was appointed as Executive Chairman at InfuSystem Holdings, Inc.

“Coincident to Ms. Lachance's appointment, Scott Shuda was appointed Executive Chairman of the Company's Board.”

Carrie Lachance was appointed as Chief Executive Officer at InfuSystem Holdings, Inc.

“The Board has appointed Carrie Lachance as the new CEO, effective as of the Separation Date.”

Richard A. DiIorio departed as Director at InfuSystem Holdings, Inc.

“will continue to serve on the Board until the end of his term, which expires May 15, 2025”

Richard A. DiIorio departed as Chief Executive Officer at InfuSystem Holdings, Inc.

“Mr. DiIorio will step down as the Company's Chief Executive Officer ("CEO"), effective May 19, 2025”

Ron Hundzinski was elected as Director at InfuSystem Holdings, Inc.

“elected Ron Hundzinski to fill the vacancy created by this increase in size of the Board of Directors.”

InfuSystem Holdings, Inc shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2024-05-16 meeting.

“Proposal No. 3: The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2024 as follows: For Against Abstain Broker Non-Votes 16,164,598 1,930,216 180,229 0”

InfuSystem Holdings, Inc shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-16 meeting.

“Proposal No. 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows: For Against Abstain Broker Non-Votes 8,447,458 7,411,428 6,763 2,409,394”

InfuSystem Holdings, Inc shareholders approved Election of Directors at the 2024-05-16 meeting.

“At the 2024 Annual Meeting of Stockholders of InfuSystem Holdings, Inc. (the "Company") held on May 16, 2024 , the matters voted upon and the number of votes for, against or withheld, as well as the number of abstentions and broker non-votes as to such matters, were as stated below: Proposal No. 1: The Company's Board Nominees For Withheld Broker Non-Votes Ralph Boyd 10,321,961 5,543,688 2,409,394 Richard DiIorio 12,564,229 3,301,420 2,409,394 Kenneth Eichenbaum 11,444,647 4,421,002 2,409,394 Paul Gendron 11,366,680 4,498,969 2,409,394 Beverly Huss 10,958,717 4,906,932 2,409,394 Carrie Lachance 12,443,248 3,422,401 2,409,394 Scott Shuda 9,810,697 6,054,952 2,409,394 All seven of the Company's Board nominees (Messrs. Boyd, DiIorio, Eichenbaum, Gendron and Shuda and Mss. Huss and Lachance) were elected to the Board.”

InfuSystem Holdings, Inc reported first quarter ended March 31, 2024 results: revenue Net revenues totaled $32.0 million, net income Net loss was $1.1 million, EPS $(0.05) per diluted share.

“• Net revenues totaled $32.0 million, an increase of 5% vs. prior year. ◦ Patient Services net revenue was $18.6 million, a decrease of 1% vs. prior year. ◦ Device Solutions net revenue was $13.4 million, an increase of 16% vs. prior year. • Gross profit was $16.5 million, an increase of 10% vs. prior year. • Gross margin was 51.5%, an increase of 2.3% vs. prior year. ◦ Patient Services gross margin was 66.0%, an increase of 4.5% vs. prior year. ◦ Device Solutions gross margin was 31.3%, an increase of 1.9% vs. prior year. • Net loss was $1.1 million, or $(0.05) per diluted share vs. prior year net loss of $0.3 million, or $(0.02) per diluted share.”

InfuSystem Holdings, Inc received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“April 2, 2024 , InfuSystem Holdings, Inc. (the "Company") received notice from the NYSE Regulation (the "Notice") stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the "Exchange") under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Delinquent Report"), which was due to be filed with the Securities and Exchange Commission (the "SEC") no later than April 1, 2024”

InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2023 results: revenue Net revenues totaled $125.8 million. Guidance reaffirmed.

“Partners, LLC 602-889-9700 InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2023 Full Year 2023 vs. Full Year 2022: Record Net Revenues: $125.8 million, a 14% increase Patient Services Revenue: $76.5 million - Device Solutions Revenue: $49.2 million, increases of 11% and 20% Adjusted EBITDA (non-GAAP): $22.4 million, an 8%”

R. Rimmy Malhotra resigned as Director at InfuSystem Holdings, Inc.

“accepted the resignation of Mr. R. Rimmy Malhotra as a member of the Board, effective March 8, 2024”

InfuSystem Holdings, Inc reported third quarter ended September 30, 2023 results: revenue $31.9 million, net income $0.7 million, or $0.03 per diluted share, EPS $0.03 per diluted share. Guidance raised.

“InfuSystem Reports Third Quarter 2023 Financial Results Record Net Revenues of $31.9 million Representing 17% Growth from the Prior Year”

InfuSystem Holdings, Inc reported second quarter ended June 30, 2023 results: revenue $31.7 million, net income $0.4 million, or $0.02 per diluted share, EPS $0.02 per diluted share. Guidance raised.

“InfuSystem Reports Second Quarter 2023 Financial Results Record Net Revenues of $31.7 million Representing 17% Growth From the Prior Year Rochester Hills, Michigan, August 3, 2023 – InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the second quarter ended June 30, 2023.”

InfuSystem Holdings, Inc engaged Deloitte & Touche LLP as its auditor.

“On July 26, 2023, the Company engaged Deloitte & Touche LLP ("Deloitte") as the Company's independent public accounting firm to audit the Company's consolidated financial statements for the fiscal year ending December 31, 2023 and to review the Company's quarterly consolidated financial statements beginning with the second quarter of the 2023 fiscal year.”

InfuSystem Holdings, Inc dismissed BDO USA, LLP as its auditor.

“on June 30, 2023 , the Committee approved the dismissal of BDO as the Company's independent registered public accounting firm”

InfuSystem Holdings, Inc shareholders approved Ratification of appointment of BDO USA, LLP as independent registered public accounting firm at the 2023-05-16 meeting.

“Proposal No. 5: The Company's stockholders ratified the appointment of BDO USA, LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2023 as follows: For Against Abstain Broker Non-Votes 16,193,894 303,881 169,335 0”

InfuSystem Holdings, Inc shareholders approved Adoption of the 2023 Employee Stock Purchase Plan at the 2023-05-16 meeting.

“Proposal No. 4: The Company's stockholders approved the adoption of the Company's 2023 Employee Stock Purchase Plan as follows: For Against Abstain Broker Non-Votes 12,322,132 967,993 8,105 3,368,880”

InfuSystem Holdings, Inc shareholders approved Amendment to the Company's 2021 Equity Plan to increase the number of authorized shares at the 2023-05-16 meeting.

“Proposal No. 3: The Company's stockholders approved the amendment to the Company's 2021 Equity Plan to increase the number of authorized shares under the 2021 Equity Plan as follows: For Against Abstain Broker Non-Votes 10,731,156 2,548,562 18,512 3,368,880”

InfuSystem Holdings, Inc shareholders approved Advisory vote on executive compensation at the 2023-05-16 meeting.

“Proposal No. 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows: For Against Abstain Broker Non-Votes 12,275,494 1,004,581 18,155 3,368,880”

InfuSystem Holdings, Inc shareholders approved Election of Directors at the 2023-05-16 meeting.

“Proposal No. 1: The Company's Board Nominees For Withheld Broker Non-Votes Ralph Boyd 11,596,126 1,702,104 3,368,880 Richard DiIorio 12,829,063 469,167 3,368,880 Paul Gendron 12,692,060 606,170 3,368,880 Carrie Lachance 12,755,114 543,116 3,368,880 Gregg Lehman 11,137,634 2,160,596 3,368,880 R. Rimmy Malhotra 10,618,480 2,679,750 3,368,880 Scott Shuda 12,163,620 1,134,610 3,368,880 All seven of the Company's Board nominees (Messrs. Boyd, DiIorio, Gendron, Lehman, Malhotra and Shuda and Ms. Lachance) were elected to the Board.”

InfuSystem Holdings, Inc amended credit facility with JPMorgan Chase Bank, N.A., as administrative agent at the replacement of LIBOR with Term SOFR as a benchmark interest rate maturing April 26, 2028.

“On April 26, 2023, InfuSystem Holdings, Inc. (the “Company”) together with its direct and indirect subsidiaries (collectively, the “Borrowers”), entered into a First Amendment to Credit Agreement (the "Amendment") with JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”) , and the lenders party thereto, which amended the Credit Agreement, dated as of February 5, 2021 (as amended by the Amendment, the “Credit Agreement”) among the Borrowers, the other loan parties party thereto, the lenders party thereto, and the Administrative Agent, providing for, among other things: (i) an extension of the maturity date for the Credit Agreement to April 26, 2028, (ii) the replacement of LIBOR with Term SOFR as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans to $35 million.”

InfuSystem Holdings, Inc amended First Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-04-26).

“On April 26, 2023 , InfuSystem Holdings, Inc. (the “Company”) together with its direct and indirect subsidiaries (collectively, the “Borrowers”), entered into a First Amendment to Credit Agreement (the "Amendment") with JPMorgan Chase Bank, N.A., as administrative agent”

Christopher Sansone departed as Director at InfuSystem Holdings, Inc.

“On March 24, 2023 , Christopher Sansone notified InfuSystem Holdings, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors”

InfuSystem Holdings, Inc reported fourth quarter and full year ended December 31, 2022 results: revenue Net revenues totaled $109.9 million, net income Net income of less than $0.1 million, EPS $0.01 per diluted share. Guidance reaffirmed.

“InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2022 Full Year 2022 vs. Full Year 2021: Record Net Revenues: $109.9 million, a 7% increase”

InfuSystem Holdings, Inc reported the third quarter ended September 30, 2022 results: revenue $27.3 million, net income $0.4 million, EPS $0.02 per diluted share.

“• Net revenues totaled $27.3 million, an increase of 3% vs. prior year. ◦ Integrated Therapy Services ("ITS") net revenue was $17.4 million, an increase of 5% vs. prior year. ◦ Durable Medical Equipment Services ("DME Services") net revenue was $9.9 million, a decrease of 1% vs. prior year. • Gross profit was $16.2 million, an increase of 6% vs. prior year. • Gross margin was 59.5%, an increase of 2.0% vs. prior year. ◦ ITS gross margin was 65.6%, an increase of 1.8% vs. prior year. ◦ DME Services gross margin was 48.7%, an increase of 1.7% vs. prior year. • Operating income increased $1.3 million to $0.9 million vs. prior year. • Net income of $0.4 million, or $0.02 per diluted share, an increase of $0.9 million vs. prior year.”

R. Rimmy Malhotra was elected as Director at InfuSystem Holdings, Inc.

“On September 20, 2022 , the Board of Directors of InfuSystem Holdings, Inc. (the “Company”) expanded the size of the Board of Directors from seven to eight members and elected R. Rimmy Malhotra to fill the vacancy created by this increase in size of the Board of Directors.”